公开(公告)号：US20250066322A1

公开(公告)日：2025-02-27

申请号：US18560520

申请日：2022-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： MICHAEL EDWARD MERTZMAN ,  RYAN M. MOSLIN ,  STEVEN H. SPERGEL ,  KARIN IRMGARD WORM

IPC: C07D401/12 ,  A61K31/444 ,  A61K31/501

Abstract: There are disclosed compounds of the following formula (I): or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US20240317718A1

公开(公告)日：2024-09-26

申请号：US18560485

申请日：2022-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： STEVEN H. SPERGEL ,  RYAN M. MOSLIN ,  MICHAEL EDWARD MERTZMAN ,  SHOSHANA L. POSY ,  SIRISH KAUSHIK LAKKARAJU ,  JOSEPH A. TINO ,  ZILI XIAO ,  CHUNJIAN LIU ,  JAMES LIN

IPC: C07D403/12 ,  A61K31/501 ,  A61K31/506 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

CPC classification number: C07D403/12 ,  A61K31/501 ,  A61K31/506 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

Abstract: There are disclosed compounds of the following formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US20240270723A1

公开(公告)日：2024-08-15

申请号：US18560496

申请日：2022-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： STEVEN H. SPERGEL ,  MICHAEL EDWARD MERTZMAN

IPC: C07D403/14 ,  A61K31/501 ,  A61K31/506 ,  C07D401/14

CPC classification number: C07D403/14 ,  A61K31/501 ,  A61K31/506 ,  C07D401/14

Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.